The Use of Angiotensin Receptor Blockers and the Risk of Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)
Exclusion Criteria:
- History of cancer at any time prior to cohort entry
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients prescribed antihypertensives
|
other than telmisartan
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs
Time Frame: 16 years
|
16 years
|
|
Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs
Time Frame: 16 years
|
16 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with occurrences of lung cancer related to use of ARBs alone
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of colorectal cancer related to use of ARBs alone
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of breast cancer related to use of ARBs alone
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of prostate cancer related to use of ARBs alone
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of lung cancer related to use of ARBs with ACEI
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of colorectal cancer related to use of ARBs with ACEI
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of breast cancer related to use of ARBs with ACEI
Time Frame: 16 years
|
16 years
|
|
Number of patients with occurrences of prostate cancer related to use of ARBs with ACEI
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of lung cancer related to use of telmisartan relative to other ARBs
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of colorectal cancer related to use of telmisartan relative to other ARBs
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of breast cancer related to use of telmisartan relative to other ARBs
Time Frame: 16 years
|
16 years
|
|
Ratio of occurrence of prostate cancer related to use of telmisartan relative to other ARBs
Time Frame: 16 years
|
16 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Telmisartan
- Diuretics
- Adrenergic beta-Antagonists
Other Study ID Numbers
Other Study ID Numbers
- 502.599
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.